Browse related articlesJulphar to invest $335m on expansion
United Arab Emirates: Wednesday, December 12 - 2007 at 08:59
UAE-based Gulf Pharmaceutical Industries (Julphar) plans to invest Dhs1.23bn ($335m) over the next three years to build new factories and expand abroad, reported Gulf News. Julphar, the biggest pharmaceutical firm in the UAE, will set up seven new manufacturing plants in Ras Al Khaimah and open manufacturing facilities in seven countries. Abdul Razzaq Al Yousef, Julphar's chief executive, said the company was also planning to open a chain of retail pharmacies across the Mena region.
See Also
Also consider reading:
- » Sharon Stone helps raise $3m for Aids
- » Doha North ponders sludge incineration
- » Abu Dhabi to recycle all treated effluent
- » UAE records 35 HIV cases among nationals
- » Third Al-Aweer sewage plant planned
- » Dubai group to invest $250m
- » New bird flu cases in four countries
- » No vaccine worries for UAE
- » Bahrain advises Hajjis
- » Eid rules for UAE doctors
Facebook
LinkedIn
Digg
Jeff Florian, Senior ReporterWednesday, December 12 - 2007 at 08:59 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds